« It's Small [Pharma] World Afterall! | Main | CEO's "When the going gets tough, the Tough get innovative" »

03/25/2010

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a0120a77f675b970b0120a97833a8970b

Listed below are links to weblogs that reference Regulatory Discipline!:

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

Bruce Lehr

Supply issues continue and regulatory agency recommends alternatives. http://bit.ly/ds4TE9

Bruce Lehr

Results from the 1st QTR 2010 are in an the effects of the quality problems were predicatable.
http://online.wsj.com/article/SB10001424052748704133804575198212277925170.html?mod=rss_Health

Bruce Lehr

Fierce Biotech provided an update on the $175 M fine that the FDA will levy on Genzyme for its manufacturing failings at its MA facility relative to Cerezyme.
http://www.fiercebiotech.com/story/decree-spells-out-175m-fine-new-penalties-genzyme/2010-04-21

Bruce Lehr

Update from Financial Times (http://bit.ly/bqSvEQ)on Friday, March 26th. Europe did approve recall of clopidogrel from 8 manufacturers in line with CHMP recommendation. It was considered precautionary. Sanofi-Aventis and BMS emphasied that their source of clopidogrel (branded Plavix) was NOT affected by this recall.

The comments to this entry are closed.

My Photo
Blog powered by Typepad
Member since 12/2009
Bookmark and Share

April 2014

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30      

Innovate on Purpose

In the Pipeline

Life Sci VC


visited 6 states (46.1%)
Create your own visited map of Canada